Gene therapy
Serving the public interest
Our mission: Conception, clinic and preclinic development of drugs of genic therapy for rare diseases
Our goal: Providing these innovative treatments to the sick
Our science
News
20 October 2021
Genethon Presents Significant Advances in Gene Therapy at European Society for Gene and Cell Therapy, Oct 19-22, 2021
(read more)
28 June 2021
Preliminary results of clinical trial for rare liver disease Crigler-Najjar syndrome presented at ESGCT congress
(read more)
23 April 2021
Genethon announces First Patient dosed in Clinical Trial of Investigational Gene therapy GNT 0004 for Duchenne Muscular Dystrophy
(read more)
28 February 2021
Genethon, 30 years of pioneering research and innovation in treating rare diseases
(read more)
10 February 2021
Genethon and WhiteLab Genomics join forces to enhance gene therapy through artificial intelligence
(read more)
3 February 2021
Genethon is delighted about the launch of a gene therapy clinical trial for late-onset Pompe disease
(read more)
2 December 2020
Genethon gets the green light from the ANSM to start an innovative gene therapy trial for Duchenne muscular dystrophy
(read more)
21 September 2020
Genethon welcomes the submission to EMA of Marketing Authorisation Application for LUMEVOQ® Gene Therapy to Treat Vision Loss due to Leber Hereditary Optic Neuropathy (LHON)
(read more)
10 June 2020
A Genethon team succeeds in inhibiting the immune response linked to AAV, opening up the possibility of treating more patients by gene therapy
(read more)
30 January 2020
Genethon welcomes the conclusive results of a gene therapy trial in Chronic Septic Granulomatosis, a rare disease of the immune system
(read more)
9 January 2020
Genethon strengthens its collaboration with Sarepta Therapeutics for the development of the gene therapy product GNT0004 in Duchenne muscular dystrophy
(read more)
9 September 2019
A gene therapy based clinical trial for Fanconi anemia patients offers its first successful results
(read more)
26 June 2019
First in vivo proof-of-concept in Steinert’s myotonic dystrophy, a neuromuscular disease
(read more)
24 May 2019
Towards a clinical trial for gamma-sarcoglycanopathy, limb-girdle muscular dystrophy
(read more)
10 December 2018
Genethon announces dosing of the first patient with Crigler–Najjar Syndrome
(read more)
5 October 2018
Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
(read more)
12 February 2018
Genethon starts a clinical trial to test a gene therapy treatment for a rare liver disease, Crigler-Najjar Syndrome
(read more)
